Valuation

Structured Products and Complex Financial Instruments

Structured Products and Complex Financial Instruments

As a pioneer in the field of asset valuation, NERA uses innovative techniques to measure value in real-world scenarios. Our valuations use real options, probability-weighted and dynamic cash flow models, the stock and debt approach to real property appraisal, and event studies to measure lost profits. Our experience in a variety of asset classes, including structured products, credit default swaps, and other complex derivatives, allows us to quickly assess market specifics and the impact of market economics on market value. The use of advanced techniques combining economics, finance, statistics, and econometrics contribute to a result that extends well beyond traditional approaches to valuation, especially in cases where historical data and other valuation benchmarks are either unavailable or considered inadequate.

Name Title Location Phone Email
Dr. Vinita Juneja Senior Managing Director
Chair of NERA's White Collar, Investigations and Enforcement Practice
New York City
London
Toronto
+1 212 345 3148
+44 20 7659 8618
+1 416 868 7314
vinita.juneja@nera.com
Dr. Denise Neumann Martin Senior Managing Director Miami +1 305 808 7880 denise.martin@nera.com
Dr. Faten Sabry Senior Managing Director
Chair of NERA's Global Securities and Finance Practice
Bankruptcy Practice Chair
New York City
London
+1 212 345 3285
+44 20 7659 8618
faten.sabry@nera.com
Kurt G. Strunk Senior Managing Director New York City +1 212 345 5035 kurt.strunk@nera.com
Dr. Ling Ling Ang Managing Director Washington, DC
Chicago
+1 202 466 9259
+312 573 2827
lingling.ang@nera.com
Dr. Vladimir Starkov Managing Director Chicago +1 312 573 2806 vladimir.starkov@nera.com
Dr. Airat Chanyshev Director New York City +1 212 345 7336 airat.chanyshev@nera.com
Timothy McKenna Director Los Angeles
New York City
+1 213 346 3041
+1 212 345 3000
timothy.mckenna@nera.com
Dr. Sharon Brown-Hruska Affiliated Consultant Washington, DC +1 202 466 3510 sharon.hruska.affiliate@nera.com
Dr. Andrew Carron Affiliated Consultant New York City
London
+1 212 345 5407
+44 20 7659 8500
andrew.carron.affiliate@nera.com
Dr. Alan Cox Affiliated Consultant San Francisco +1 415 291 1000 alan.cox.affiliate@nera.com
Mike King Affiliated Consultant Denver
San Francisco
Washington, DC
+1 303 357 4781
+1 303 618 4915
+1 303 618 4915
mike.king.affiliate@nera.com
Dr. Alexander Voegele Affiliated Consultant Frankfurt +49 69 710 447 501 alexander.voegele.affiliate@nera.com
Title Type Author
Recent Trends in Securities Class Action Litigation: H1 2023 Update Report Edward Flores and Svetlana Starykh
Snapshot of Recent Trends in Asbestos Litigation: 2022 Update White Paper Mary Elizabeth Stern and Lucy Allen
How Will the LIBOR Transition Affect Mortgage Consumers? White Paper Dr. Faten Sabry and Ramisa Roya, et al.
Trends in Canadian Securities Class Actions: 2021 Update White Paper Bradley A. Heys, Robert Patton, Jielei Mao
‘Coca-Cola’ vs. Section 482: Is It Time to Refresh the Regulatory Guidance? Published Article Dr. Harlow Higinbotham and Dr. Niraja Srinivasan
Snapshot of Recent Trends in Asbestos Litigation 2021 Update Mary Elizabeth C. Stern and Lucy P. Allen
NERA Experts Contribute Chapter to "The Future of the Profit Split Method" Book Dr. Harlow Higginbotham and Dr. Vladimir Starkov
Trends in Canadian Securities Class Actions: 2020 Update Report Bradley A. Heys, Robert Patton, and Jielei Mao
Transfer Pricing Roundtable in Financier Worldwide. Expert QA Dr. Vladimir Starkov and Philip de Homont
Amount B: Facts and Circumstances Matter—Even for Routine Distributors Published Article Dr. Harlow Higinbotham and Dr. Vladimir Starkov